QIAGEN Surpasses Q1 2025 Outlook, Raises Full-Year EPS Forecast
QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced strong preliminary results for the first quarter of 2025, surpassing both its previous guidance for net sales and adjusted earnings per share (EPS). This positive performance reflects the company’s solid growth in several key areas.
For the first quarter of 2025, QIAGEN’s net consolidated sales increased by approximately 5%, or 7% at constant exchange rates (CER), reaching around $483 million. This performance exceeded the previously anticipated growth of around 3% CER. When excluding discontinued product lines such as NeuMoDx and Dialunox, QIAGEN’s core business experienced a 4% CER growth. Additionally, the company expects adjusted diluted earnings per share to be at least $0.55, which is higher than the previous guidance of approximately $0.50 CER.
One of the major contributors to QIAGEN’s strong sales growth was the continued success of its QuantiFERON test for latent tuberculosis, which saw a 15% CER growth. This growth was fueled by the ongoing global shift from traditional skin testing to the more modern and reliable blood-based QuantiFERON test. Another key factor was the impressive performance of QIAGEN’s QIAstat-Dx syndromic test system, which grew by more than 35% CER. This growth was driven by the continued demand for respiratory panels, as well as increased testing in gastrointestinal and meningitis-related areas. Additionally, the QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business each experienced high single-digit CER growth, reflecting strong demand across both research and clinical sectors.
Sales of PCR consumables and original equipment manufacturer (OEM) products also contributed to QIAGEN’s solid performance. However, sales of sample technologies declined by 1% CER, primarily due to cautious spending on life sciences instruments by certain customers.
With this positive momentum, QIAGEN is raising its full-year 2025 guidance for adjusted diluted earnings per share. The company now expects adjusted EPS to be around $2.35 CER, an increase from its previous forecast of approximately $2.28 CER. Furthermore, QIAGEN is reaffirming its goal to achieve an adjusted operating margin above 30% for the full year 2025. This outlook reflects not only the strong sales growth experienced in Q1 but also the favorable tax environment and potential headwinds from the recently announced U.S. import tariffs.
QIAGEN plans to provide a more detailed updated outlook for the full year 2025 during the release of its complete first-quarter 2025 results on May 7, 2025. Additionally, the company expects to achieve its medium-term target of an adjusted operating profit margin of at least 31% much sooner than previously anticipated, possibly before the original target year of 2028. This accelerated timeline is attributed to the better-than-expected performance in both 2024 and 2025.
QIAGEN, headquartered in the Netherlands, is a leading global provider of solutions for gaining molecular insights from biological samples. The company’s diverse product portfolio includes technologies for sample purification and processing, assay technologies for biomolecule analysis, and bioinformatics software for interpreting data and generating actionable insights. QIAGEN’s solutions are widely used in life sciences research, pharmaceutical R&D, forensics, and clinical healthcare diagnostics.
As of December 31, 2024, QIAGEN employed more than 5,700 people globally across over 35 locations. With its comprehensive range of products and services, QIAGEN serves more than 500,000 customers worldwide, including academic researchers, pharmaceutical companies, and healthcare providers.
In conclusion, the strong first-quarter performance underscores the company’s robust growth across several key product categories. The company’s positive results not only reflect the continued success of its core products but also its ability to adapt to market demands and capitalize on emerging trends in molecular diagnostics and research. With its revised earnings forecast and accelerated operating margin goals, it is well-positioned for sustained growth throughout 2025 and beyond.
